NATCOPHARM · NSE
Natco Pharma Limited
₹813.4
-0.59% (-₹4.85)
Prev. close
₹818.25
Volume
4,89,351
Delivery %
60.9%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Natco Pharma Limited
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Agrochemicals. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management of insects, fungicides, herbicides, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Rajeev Nannapaneni
Headquarters
Hyderabad
Employees
4,433
Website
natcopharma.co.inExchange
View on NSE ↗Key stats
Market cap
₹14,834.79 Cr
P/E ratio (TTM)
12.7
Dividend yield
0.73%
EPS (TTM)
₹63.91
Beta (1Y · daily vs NIFTY 50)
1.04
Beta (5Y · monthly vs NIFTY 50)
0.93
Shares float
8.37 Cr
EPS · quarter ended Jun 2026
₹11.53
Upcoming earnings
12 Nov 2026
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹2,052.10 Cr | ₹1,944.80 Cr | ₹2,707.10 Cr | ₹3,998.80 Cr | ₹4,429.50 Cr | ₹4,078.30 Cr | |
| EBITDA | ₹709.80 Cr | ₹362.50 Cr | ₹1,040.20 Cr | ₹1,879.50 Cr | ₹2,550.50 Cr | ₹1,734.10 Cr |
| ₹440.90 Cr | ₹170.00 Cr | ₹715.30 Cr | ₹1,388.30 Cr | ₹1,885.40 Cr | ₹1,418.50 Cr | |
| Diluted EPS | ₹24.16 | ₹9.32 | ₹39.18 | ₹77.34 | ₹105.26 | ₹79.2 |
Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, Pretax income, Tax provision, Interest expense, Other income have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,791.90 Cr | ₹5,109.10 Cr | ₹5,657.40 Cr | ₹6,906.30 Cr | ₹8,630.80 Cr | ₹11,073.70 Cr | |
| — | — | ₹176.10 Cr | ₹371.20 Cr | ₹279.40 Cr | ₹713.90 Cr | |
| Stockholders' equity | ₹4,121.60 Cr | ₹4,263.60 Cr | ₹4,873.80 Cr | ₹5,853.10 Cr | ₹7,607.00 Cr | ₹9,221.10 Cr |
Fixed assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹298.80 Cr | ₹46.50 Cr | ₹849.10 Cr | ₹1,211.60 Cr | ₹1,696.80 Cr | ₹1,768.30 Cr | |
| Investing cash flow | ₹-103.30 Cr | ₹-5.30 Cr | ₹-477.10 Cr | ₹-1,032.70 Cr | ₹-1,414.50 Cr | ₹-2,081.70 Cr |
| ₹-185.70 Cr | ₹34.80 Cr | ₹-363.00 Cr | ₹-246.90 Cr | ₹-210.70 Cr | ₹297.50 Cr | |
| Capital expenditure | ₹-441.50 Cr | ₹-272.00 Cr | ₹-205.60 Cr | ₹-358.70 Cr | ₹-511.60 Cr | ₹-391.10 Cr |
| End cash position | ₹25.80 Cr | ₹111.10 Cr | ₹131.90 Cr | ₹70.40 Cr | ₹120.00 Cr | ₹198.90 Cr |
Depreciation & amortization, Change in working capital, Debt issued, Dividends paid have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23 | Jun 23 | Sep 23–Jun 24(4Q) | Sep 24–Dec 24(2Q) | Mar 25–Jun 25(2Q) | Sep 25–Dec 25(2Q) | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 48.87% | 48.86% | 48.81% | 48.80% | 48.82% | 48.84% | 49.76% | 49.71% | 49.62% | 49.56% | 49.48% | 49.42% |
| Public | 51.13% | 51.14% | 51.19% | 51.20% | 51.18% | 51.16% | 50.24% | 50.29% | 50.38% | 50.44% | 50.52% | 50.58% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Natco Pharma Limited | ₹14,832.96 Cr | ₹818.25 | 12.7 | 1.61 | 15.4% | 0.08 | -8.3% | -4.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
29 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma sector stocks today, September 17: Panacea Biotech gains 2.27%, Alembic Pharma up 2.13%, Wockhardt rises 2%
Business Upturn · 2 days ago
Pharma sector stocks fall today, September 16: Aarti Drugs down 2.30%, Natco Pharma declines 2%, Glenmark Pharma falls 1.47%
Business Upturn · 3 days ago